Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2
Molecules · 28.06.2024 · 29 (13) · 3093
DOI: 10.3390/molecules29133093 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Molecules, online erschienen am 28.06.2024. Verfasst von Tilman Läppchen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, Bern University Hospital, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Radiopharmaceuticals, Gallium Radioisotopes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe Research and Innovation programme under the Marie Skłodowska-Curie Action, European Union’s Horizon Europe Research and Innovation program under the Marie Skłodowska-Curie Action (OncoProTools).
Abstract (Originalsprache)
Background
FAP radiopharmaceuticals show promise for cancer diagnosis; however, their limited tumor residency hinders treatment. This study compared two FAPi derivatives, DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2, labeled with gallium-68 and lutetium-177, aiming to determine an optimum combination for creating theranostic pairs.
Methods
The radiotracers were studied for lipophilicity, binding to human serum proteins, and binding to human cancer-associated fibroblasts (CAFs) in vitro, including saturation and internalization/externalization studies. PET/SPECT/CT and biodistribution studies were conducted in PC3 and U87MG xenografts for [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTAGA.(SA.FAPi)2. [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2, were evaluated in PC3 xenografts. Biodistribution studies of [68Ga]Ga-DOTA.SA.FAPi were performed in healthy male and female mice.
Results
All radiotracers exhibited strong binding to FAP. Their internalization rate was fast while only [177Lu]Lu-DOTAGA.(SA.FAPi)2 was retained longer in CAFs. [68Ga]Ga-DOTAGA.(SA.FAPi)2 and [177Lu]Lu-DOTAGA.(SA.FAPi)2 displayed elevated lipophilicity and affinity for human serum proteins compared to [68Ga]Ga-DOTA.SA.FAPi and [177Lu]Lu-DOTA.SA.FAPi. In vivo studies revealed slower washout of [68Ga]Ga-DOTAGA.(SA.FAPi)2 within 3 h compared to [68Ga]Ga-DOTA.SA.FAPi. The tumor-to-tissue ratios of [68Ga]Ga-DOTAGA.(SA.FAPi)2 versus [68Ga]Ga-DOTA.SA.FAPi did not exhibit any significant differences. [177Lu]Lu-DOTAGA.(SA.FAPi)2 maintained a significant tumor uptake even after 96 h p.i. compared to [177Lu]Lu-DOTA.SA.FAPi.
Conclusions
Dimeric compounds hold promise for therapy, while monomers are better suited for diagnostics. Finding the right combination is essential for effective disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
- Department of Chemistry-TRIGA Site, Johannes Gutenberg-University Mainz, 55128 Mainz, Germany.
ORCID-Profile: Tilman Läppchen, Surachet Imlimthan, Axel Rominger
Förderung
- European Union's Horizon Europe Research and Innovation programme under the Marie Skłodowska-Curie Action
- European Union’s Horizon Europe Research and Innovation program under the Marie Skłodowska-Curie Action (OncoProTools)
Zitieren
APA
Läppchen, T., Bilinska, A., Pilatis, E., Menéndez, E., Imlimthan, S., Moon, E. S., Afshar-Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2024). Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2. Molecules, 29(13), 3093. https://doi.org/10.3390/molecules29133093
Vancouver
Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, et al. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2. Molecules. 2024;29(13):3093. doi:10.3390/molecules29133093
BibTeX
@article{Lppchen2024,
author = {Läppchen, Tilman and Bilinska, Adrianna and Pilatis, Eirinaios and Menéndez, Elena and Imlimthan, Surachet and Moon, Euy Sung and Afshar-Oromieh, Ali and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
title = {Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2},
journal = {Molecules},
year = {2024},
volume = {29},
number = {13},
pages = {3093},
doi = {10.3390/molecules29133093}
}
EUVIMED